Sept 19 (Reuters) - Perrigo Co (PRGO.O) said it received final approval from U.S. health regulators for Ciclopirox topical solution, a generic version of Sanofi-Aventis' (SASY.PA) Penlac nail-fungus treatment.
The generic drugmaker said brand sales for Penlac for the last 12 months ending August were $92 million, citing data from publisher Wolters Kluwer. (Reporting by Neha Pathania in Bangalore)
WASHINGTON (Reuters) - A broad healthcare overhaul passed its first crucial test in the U.S. Senate on Monday, with 60 Democrats voting to put President Barack Obama's top legislative priority on a path to passage by Christmas. | Video
On the last day of every month, shoppers at Walmart load their carts with food and household items and wait for the midnight hour. Is this the new normal in America? Full Article
The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
